The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
about
HIV infection and older Americans: the public health perspectiveTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?HIV and kidney diseases: 35 years of history and consequencesRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirDrug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic StudyA Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 InfectionLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeSystemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Renal impairment in a rural African antiretroviral programme.Tenofovir-associated bone density loss.COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transportersRenal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.Aging, human immunodeficiency virus, and bone health.Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineThe New Epidemiology of HIV-Related Kidney Disease.Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionRenal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimensExpert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialGenetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionNew approaches in the management of chronic hepatitis B: role of tenofovir.WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.HIV infection in the elderlyAging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in miceTenofovir-associated renal dysfunction in clinical practice: An observational cohort from western IndiaA consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.An update on the use of Atripla in the treatment of HIV in the United States.Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study.
P2860
Q26858824-F87A81E9-6AFC-447B-A7D9-B0AE0BC1ECC1Q26995852-D9C0D8E7-5500-4797-9AAB-3919748B2A7EQ28069641-B7BF1947-1CF1-44F2-B4FB-817C4526E566Q28533242-EAD0026B-EE98-4CFE-93B3-36434F0D3F24Q28550681-2D93FBB4-8CA5-47D8-968A-B690924272FEQ28552839-23EB5890-8BD0-4C23-AAE6-7B7B3B6D9DCDQ28554567-6D245892-5C98-43DB-8010-2F9D6EE7D840Q30744184-681FA5B9-5AEA-4D1D-A15D-7E7B7D824812Q31028855-C7BCCD65-044E-4817-AA69-1726D59F0453Q33498149-08B80514-CCF6-4B89-824E-4A71B9D9181EQ33635034-6D8B8D28-1D0B-469E-8EA7-5B3AC0D0038EQ33640397-58D789CF-FB52-4B7F-85EB-30A80ED654FDQ33845879-DA0CDEB4-F1EE-4FD0-A4F3-B7D7D222F8F5Q34126724-5617D8D3-7E41-4D56-8CAB-9968326A6947Q34160511-CC73125B-7121-4F56-82C5-7EE7FC97488DQ34250879-1D5398D5-9E72-43A8-BE60-5E3591CDEA5FQ34307868-9965995F-6E81-4050-95D5-A9A748423879Q34371989-93F41494-173E-4503-9196-3A36AE346A3BQ34481359-0E353A13-ACE9-463B-B561-BDF38E29070EQ34488494-7DDAE93F-A228-41D6-A5EA-9332BE2F9E72Q34686870-2B0F14F9-2D37-41EF-BEF4-E429146DBFFCQ34736194-B86FC919-637D-4150-A2B5-417137EBBFF4Q34952127-8AEC04E0-0E92-460F-A1C5-321A4A34C453Q35016654-49776D40-6A93-478C-A4DF-083C5E8705D8Q35026531-74AAD52D-FE06-4D98-A989-EC918FBB6696Q35040358-AA8FB96F-7F3E-4DB4-90DC-81B5880A04A5Q35054462-8D4D8E41-71CA-428B-AABA-13703C298AEFQ35086332-012A0853-25AB-4F00-B645-190F54839334Q35088160-9D148E2A-6069-4EC8-852B-2C0786415473Q35091774-167CFFF6-C99A-4E3C-993F-336E04F31E65Q35102322-D6573AE1-A4E3-4B07-ADD1-02E47ECEF67DQ35117296-4642CC06-78B9-405F-B4D7-C7716DF51C77Q35149475-7078B670-D21F-4F97-9130-BB6E64260A5AQ35170350-3410ED5E-3857-4523-A30F-218DAF7BF67DQ35549179-459F88B7-1D11-4AB5-AACB-4C3AE1026024Q35557269-5D1AA56B-E3A1-4CF3-BFCE-B919A8A8615CQ35575721-3EBDEDD4-CC50-4A16-A194-FF7CDDECA9FDQ35748339-6FC77170-3949-4C77-A044-CE43CC1120A0Q35891568-550DA3E0-B5B2-4EB6-9B29-F1AC103D6A9FQ35975345-48BF960E-44F3-4B33-B2C7-BE2953FFC9C2
P2860
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The safety of tenofovir disopr ...... in adults: the first 4 years.
@en
The safety of tenofovir disopr ...... in adults: the first 4 years.
@nl
type
label
The safety of tenofovir disopr ...... in adults: the first 4 years.
@en
The safety of tenofovir disopr ...... in adults: the first 4 years.
@nl
prefLabel
The safety of tenofovir disopr ...... in adults: the first 4 years.
@en
The safety of tenofovir disopr ...... in adults: the first 4 years.
@nl
P2093
P50
P1433
P1476
The safety of tenofovir disopr ...... in adults: the first 4 years.
@en
P2093
Brian Gazzard
Christina Wyatt
David A Cooper
James F Rooney
Joep Lange
Julio S Montaner
Knud Schewe
Mark R Nelson
Norbert Bischofberger
Shan-Shan Chen
P304
P356
10.1097/QAD.0B013E3280B07B33
P407
P577
2007-06-01T00:00:00Z